IP Library › Granted Patent US 12,066,431
Granted Patent B2
US 12,066,431 · App. 17/201,036 · Granted Aug 20, 2024

Human trophoblast stem cells and uses thereof

Inventors: Jau-Nan Lee (Kaohsiung, TW); Tony Tung-Ying Lee (Yakima, WA); Yuta Lee (Kaohsiung, TW)
Assignee: Accelerated Biosciences Corp.
G01N33/5073A61K35/39A61K35/54A61K39/395C12N5/0605C12N5/0606C12N5/0677A61K35/12C12N2500/34C12N2500/38C12N2500/44C12N2501/115C12N2506/02C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,066,431
App. No.
17/201,036
Granted
Aug 20, 2024
Kind
B2
Abstract

Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.

Claims (9)

1. A method for treating a Parkinson's disease or disorder in a subject in need thereof, comprising administering to a striatum region of the subject an effective amount of an isolated human villous trophoblast stem cell, wherein the isolated human villous trophoblast stem cell expresses transcripts for SSEA-1, SSEA-3, SSEA-4, Oct4, FGFR2, and FGF4, and wherein the isolated human villous trophoblast stem cell is administered to the subject via injection, transplantation, or a surgical operation.

2. The method of claim 1 , wherein the subject is a mammal.

3. The method of claim 2 , wherein the mammal is a human.

4. The method of claim 1 , wherein the isolated human villous trophoblast stem cell is isolated from trophoblast tissue.

5. The method of claim 1 , further comprising administering to the subject an effective amount of a therapeutic compound, wherein the therapeutic compound comprises a drug, a chemical, or an antibody.

6. The method of claim 1 , wherein the isolated human villous trophoblast stem cell is formulated for administration to the subject with a pharmaceutically acceptable carrier.

7. The method of claim 6 , wherein the pharmaceutically acceptable carrier maintains bioactivities of the isolated human villous trophoblast stem cell.

8. The method of claim 6 , wherein the pharmaceutically acceptable carrier comprises saline or phosphate buffered saline (PBS).

9. The method of claim 1 , wherein the isolated human villous trophoblast stem cell has a normal karyotype.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2022
From: LEE, JAU-NAN; LEE, TONY TUNG-YING; LEE, YUTA
To: ACCELERATED BIOSCIENCES CORP.
Reel/Frame 061655/0610 →
Continuity (10)
Continuation 16922595 · Jul 7, 2020
Continuation 15892777 · Feb 9, 2018
Division 14840970 · Aug 31, 2015
Continuation 13909469 · Jun 4, 2013
Division 13415595 · Mar 8, 2012
Division 12972237 · Dec 17, 2010
Division 12405112 · Mar 16, 2009
Division 11361588 · Feb 24, 2006
Provisional Application 60655747 · Feb 24, 2005
Related Publication 20210278395A1 · Sep 9, 2021